| Bioactivity | CQ211 is a potent and selective RIOK2 inhibitor with a Kd of 6.1 nM. CQ211 exhibits potent proliferation inhibition activity against multiple cancer cell lines[1]. |
| Target | Kd: 6.1 nM (RIOK2) |
| In Vivo | CQ211 (25 mg/kg) inhibits the tumor progression with tumor growth inhibition (TGI) of 30.9% in rats[1]. |
| Name | CQ211 |
| CAS | 2648986-65-4 |
| Formula | C26H22F3N7O2 |
| Molar Mass | 521.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ouyang Y, et al. Discovery of 8-(6-Methoxypyridin-3-yl)-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1,5-dihydro-4H-[1,2,3]triazolo[4,5-c]quinolin-4-one (CQ211) as a Highly Potent and Selective RIOK2 Inhibitor. J Med Chem. 2022 Jun 9;65(11):7833-7842. |